Načítá se...
Anti-CTLA-4 therapy results in higher CD4(+)ICOS(hi) T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
Cytotoxic lymphocyte antigen-4 (CTLA-4) blockade is an active immunotherapeutic strategy that is currently in clinical trials in cancer. There are several ongoing trials of anti-CTLA-4 in the metastatic setting of prostate cancer patients with reported clinical responses consisting of decreases in t...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
National Academy of Sciences
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2650334/ https://ncbi.nlm.nih.gov/pubmed/19202079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0813175106 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|